Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-05

Clinical Trial Update: Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function [Phase 2]

View source ↗

Summary

Phase 2 trial update on eltrombopag for poor graft function has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eltrombopag (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Poor Graft Function | Phase 2 | Status: TERMINATED | Results posted: 2024-02-05